In November 2023, the UK Joint Committee on Vaccination and Immunisation (JCVI) recommended the introduction of a universal childhood varicella (chickenpox) vaccination programme. The vaccine will be administered as part of a combined measles, mumps, rubella, and varicella (MMRV) vaccine from 2026. This article explores the rationale for introducing the chickenpox vaccine in the UK, its potential public health impact, the possible implications for uptake of the MMR vaccine, and the role of nurses in supporting implementation. It describes the evidence from other countries which demonstrates significant reductions in varicella incidence, complications, and hospitalisations following vaccination, and the influence on the JCVI’s decision of updated cost-effectiveness modelling, reduced post-pandemic immunity, and public health alignment with international practice. It further discusses potential challenges, including public perceptions of necessity, the small risk of febrile seizures with MMRV, and the risk that vaccine hesitancy will affect MMR uptake.